Comparing the effect of topical 1% Avy extract gel with 1% Diclofenac gel in the treatment of patients with primary knee osteoarthritis referred to orthopedic clinic

Comparing the effect of topical 1% Hedera helix L. extract gel with 1% Diclofenac gel in the treatment of patients with primary knee osteoarthritis referred to orthopedic clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017050133740N1

Enrollment

150

Registered

2017-09-26

Start date

2017-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gonarthrosis. Other primary gonarthrosis Primary gonarthrosis: NOS unilatera

Interventions

Intervention 1: 1% Hedera helix extract gel, topical use, three times a day. Intervention 2: 1% Diclofenac gel, topical use, three times a day. Intervention 3: Placebo gel, topical use, three times a

Treatment - Drugs

Placebo

1% Hedera helix extract gel, topical use, three times a day.

1% Diclofenac gel, topical use, three times a day.

Placebo gel, topical use, three times a day.

Eligibility

Sex/Gender

All

Age

45 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Primary osteoarthritis in at least one knee confirmed radiologicaly on a knee x-ray; Pain presence from at least 2 weeks prior to visit; Age> 45. Exclusion criteria: Secondary osteoarthritis; Active liver or kidney disease; Peptic ulcer disease; Diabetes; Thyroid or parathyroid diseases; Coagulopathy or taking anti-coagulatory drugs; Ischemic or hemorrhagic CVA; Past history of deep vein thrombosis; Allergy to any form of anti-inflammatory agents, Acute trauma; Alcohol use; Drug abuse; Skin diseases, infection or wound on the site of the study; Corticosteroid use in any form; Using other topical agents on the site of the study; Taking oral agents effective on osteoarthritis within 10 days from the start of the study; Pregnancy; History of the site fracture; Deformities leading to osteoarthritis; Congenital joint diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Morning stiffnes. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Stiffness during the day. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Physical function. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.	—

Measure

Time frame

Pain. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Morning stiffnes. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Stiffness during the day. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.;Physical function. Timepoint: Before and after intervention. Method of measurement: VAS and WOMAC questionnaires.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdie Saffari

Shahrekord University of Medical Sciences

mahdiesaffari@yahoo.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026